- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.50 Å
- Oligo State
- hetero-2-2-mer
- Ligands
- 4 x CMO: CARBON MONOXIDE(Non-functional Binders)
CMO.1: 4 residues within 4Å:- Chain A: F.44, H.59, H.88
- Ligands: HEM.2
No protein-ligand interaction detected (PLIP)CMO.3: 6 residues within 4Å:- Chain B: L.30, F.44, H.65, V.69, H.94
- Ligands: HEM.4
1 PLIP interactions:1 interactions with chain B- Hydrogen bonds: B:H.65
CMO.5: 5 residues within 4Å:- Chain C: L.30, F.44, H.59, H.88
- Ligands: HEM.6
No protein-ligand interaction detected (PLIP)CMO.7: 6 residues within 4Å:- Chain D: L.30, F.44, H.65, V.69, H.94
- Ligands: HEM.8
No protein-ligand interaction detected (PLIP)- 4 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)
HEM.2: 21 residues within 4Å:- Chain A: M.33, Y.43, F.44, H.46, F.47, H.59, K.62, V.63, A.66, L.67, L.84, L.87, H.88, L.92, V.94, N.98, F.99, L.102, V.133, L.137
- Ligands: CMO.1
19 PLIP interactions:18 interactions with chain A, 1 Ligand-Ligand interactions- Hydrophobic interactions: A:F.44, A:F.44, A:V.63, A:A.66, A:L.84, A:L.84, A:L.87, A:L.92, A:V.94, A:N.98, A:F.99, A:L.102, A:L.102, A:V.133, A:L.137
- Salt bridges: A:H.46, A:H.59
- Metal complexes: A:H.88, CMO.1
HEM.4: 23 residues within 4Å:- Chain B: L.33, T.40, F.43, F.44, S.46, F.47, H.65, K.68, V.69, A.72, F.73, F.87, L.90, L.93, H.94, L.98, V.100, N.104, F.105, L.108, V.139, L.143
- Ligands: CMO.3
24 PLIP interactions:24 interactions with chain B,- Hydrophobic interactions: B:L.33, B:T.40, B:F.43, B:F.43, B:F.44, B:F.44, B:F.44, B:F.73, B:F.73, B:F.87, B:L.90, B:L.90, B:L.93, B:L.98, B:N.104, B:F.105, B:F.105, B:L.108, B:V.139, B:L.143
- Hydrogen bonds: B:S.46
- Salt bridges: B:H.65, B:K.68
- Metal complexes: B:H.94
HEM.6: 18 residues within 4Å:- Chain C: Y.43, F.44, F.47, H.59, K.62, V.63, A.66, L.67, L.84, H.88, L.92, V.94, N.98, F.99, L.102, S.134, L.137
- Ligands: CMO.5
21 PLIP interactions:21 interactions with chain C,- Hydrophobic interactions: C:Y.43, C:Y.43, C:F.44, C:F.44, C:F.47, C:V.63, C:A.66, C:L.67, C:L.84, C:L.84, C:L.92, C:L.92, C:V.94, C:V.94, C:F.99, C:F.99, C:L.102, C:L.102, C:L.137
- Salt bridges: C:K.62
- Metal complexes: C:H.88
HEM.8: 18 residues within 4Å:- Chain D: T.40, F.43, F.44, F.47, H.65, K.68, V.69, A.72, F.73, L.90, H.94, L.98, V.100, N.104, F.105, L.108, L.143
- Ligands: CMO.7
19 PLIP interactions:18 interactions with chain D, 1 Ligand-Ligand interactions- Hydrophobic interactions: D:T.40, D:F.43, D:F.43, D:F.44, D:F.44, D:F.44, D:K.68, D:F.73, D:F.73, D:L.90, D:L.98, D:V.100, D:V.100, D:N.104, D:L.108, D:L.143
- Salt bridges: D:H.65
- Metal complexes: D:H.94, CMO.7
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Demers, M. et al., MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. Blood Adv (2021)
- Release Date
- 2021-10-13
- Peptides
- Hemoglobin subunit alpha: AC
Hemoglobin subunit beta: BD - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GC
IB
HD
J
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.50 Å
- Oligo State
- hetero-2-2-mer
- Ligands
- 4 x CMO: CARBON MONOXIDE(Non-functional Binders)
- 4 x HEM: PROTOPORPHYRIN IX CONTAINING FE(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Demers, M. et al., MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease. Blood Adv (2021)
- Release Date
- 2021-10-13
- Peptides
- Hemoglobin subunit alpha: AC
Hemoglobin subunit beta: BD - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GC
IB
HD
J